Dr Su Pin Choo, Curie Oncology, Singapore, presenting Immunoscore® as the tool to identify with confidence who really needs chemotherapy in stage II and who will benefit from 3 versus 6 months of chemotherapy in stage III Colon Cancer

Dr Mellor, Subang Jaya Medical Centre (SJMC) Malaysia, current President of The Malaysian Oncological Society, explains why and how he is using Immunoscore® in Stage III colon cancer patients
Dr Juan Manuel O’Connor, Instituto Alexander Fleming in Buenos Aires, Argentina, testifies about the challenges to manage early colon cancer patients and the added-value of using Immunoscore® in routine practice

Professor Yoshino, National Cancer Center Hospital East (NCCE) in Chiba, Japan, talks about Immunoscore® and its clinical performance in the Asian population